Ensysce Biosciences, Inc.
ENSCNASDAQHealthcare● Active
$0.25
$-0.01(-2.75%)
Market Cap$2292549
P/E Ratio—
52W High$2.75
52W Low$0.23
Ensysce Biosciences, Inc. (ENSC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ENSC · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M |
| Cost of Revenue | $0.00M | $7.22M | $7.59M | $19.84M | $0.00M |
| Gross Profit | $0.00M | ($2.01M) | ($5.36M) | ($17.31M) | $3.53M |
| Gross Margin %(computed) | 0.00% | -38.57% | -240.12% | -686.08% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M |
| G&A Expenses | $4.93M | $4.72M | $5.36M | $6.91M | $0.00M |
| Total Operating Expenses | $10.24M | $4.72M | $5.36M | $6.91M | $23.40M |
| Operating Income | ($10.24M) | ($6.73M) | ($10.72M) | ($24.22M) | ($19.87M) |
| Operating Margin %(computed) | -202.12% | -129.17% | -480.41% | -959.91% | -562.71% |
| Interest Income | $0.00M | $0.00M | $0.00M | $1.25M | $3.21M |
| Interest Expense | $0.02M | $1.29M | $0.35M | $0.11M | $1.29M |
| Income Before Tax | ($10.18M) | ($7.99M) | ($10.63M) | ($24.21M) | ($29.15M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($10.18M) | ($7.99M) | ($10.61M) | ($24.17M) | ($29.08M) |
| Net Margin %(computed) | -200.84% | -153.30% | -475.71% | -957.93% | -823.62% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.98 | $-4.57 | $-4.69 | $-139.44 | $-355.68 |
| Wtd Avg Shares | 2.56M | 1.75M | 2.26M | 0.18M | 0.08M |
| EBITDA | ($10.15M) | ($6.73M) | ($10.72M) | ($24.22M) | ($25.93M) |
| EBITDA Margin %(computed) | -200.35% | -129.17% | -480.41% | -959.90% | -734.32% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Ensysce Biosciences, Inc. data
About Ensysce Biosciences, Inc. (ENSC) Income Statement
Ensysce Biosciences, Inc. (ENSC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ENSC reported revenue of $0.01B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.01B) — a net profit margin of -200.84%.
Frequently asked questions
ENSC · 4 questionsEnsysce Biosciences, Inc. (ENSC) reported revenue of $0.01B for 2025, down 2.8% year-over-year.
ENSC revenueENSC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08